Peptides in 2026

Quick Summary: A subcutaneous (SC) injection delivers medication into the fat layer between your skin and muscle. Common sites include the lower abdomen, outer thigh, and upper arm. Depending on your needle length, you inject at a 45° or 90° angle. Always rotate sites to protect your tissue. 1. What Is a Subcutaneous Injection? A subcutaneous (SC) injection places medication into the fat layer just below your skin. Fat tissue has a smaller blood supply than muscle. Because of this, your body absorbs the medication slowly and steadily. Route Comparison Injection Type Target Layer Angle Typical Absorption Subcutaneous (SC) Fat tissue below skin 45° or 90° Slow and steady Intramuscular (IM) Deep muscle tissue 90° Rapid Intravenous (IV) Directly into a vein 15°–30° Immediate 2. Dynamic Injection Helper Find Your Angle and Pinch Needle length 4mm – 8mm (short) 10mm – 12mm+ (long) Your body type Average or higher body fat Slender or l...

Receptor Pharmacology · Eli Lilly Research Laboratories Kyle W. Sloop the scientist who explained why tirzepatide works From an evening PhD program in Indianapolis to corresponding authorship on the papers that decoded tirzepatide's receptor pharmacology — and then helped move GLP‑1 medicine from the needle to the pill. GLP‑1 receptor, ligand-bound orthosteric pocket — the structure Sloop's team solved to explain both peptide and nonpeptide agonism Raised Greenwood, Indiana Field Molecular pharmacology, GPCR structural biology Post Diabetes, Obesity and Complications, Lilly Research Laboratories Education B.S. Biology, IU Bloomington · Ph.D. Molecular Biology & Biochemistry, IUPUI, 2001 When tirzepatide outperformed selective GLP‑1 drugs in ea...

Profiles in Metabolic Medicine · A Long-Form Scientific Profile The Master of Molecules Dr. Brian Finan and the architecture of modern obesity medicine — how a peptide chemist engineered the unimolecular dual agonist, rehabilitated glucagon, and fundamentally rewrote the rules of how we treat metabolic disease. A 3,500-word profile Bloomington → Munich → Indianapolis August 2026 In this article The Incretin Problem The Bloomington Crucible The Munich Synthesis The 2013 Paradigm Shift Rehabilitating Glucagon The Novo Nordisk Vanguard The Quintuple Horizon The Ultimate Homecoming A Life in Milestones In the late 2000s, the pharmaceutical industry faced a frustrating paradox. They had discovered a miracle hormone: GLP-1. Drugs that mimicked glucagon-like peptide-1 lowered blood sugar brilliantly and helped patients lose weight. But they hit a ceiling. The biology of the human gut, it turned out, does not rely o...

Profiles in Metabolic Medicine · A Long-Form Scientific Profile The Architect of the Dual Agonist Dr. Tamer Coskun and the making of tirzepatide — how a Turkish-trained physician-scientist, working quietly inside Eli Lilly, turned a two-hormone hypothesis into one of the most consequential medicines of the twenty-first century. A 3,500-word profile Istanbul → Indianapolis August 2026 Dr. Tamer Coskun, MD, PhD. Vice President–Medical, Eli Lilly and Company — the translational architect behind tirzepatide (Mounjaro/Zepbound) and co-architect of the triple-agonist retatrutide. In this article The Bosphorus years The American apprenticeship The two-hormone hypothesis Engineering LY3298176 The clinical gauntlet The triple-agonist horizon The translator’s philosophy A life in milestones Conclusion: the molecule as monument There are moments when the center of gravity of an entire field of medicine shi...